Pfizer is partnering with The Scripps Research Institute, a non-profit biomedical research institute, to pioneer DNA-encoded library (DEL) technology to assist with early stage drug discovery research.
Under the terms of the collaboration, Pfizer will pay a technology access fee to gain access to chemical synthesis technology developed at The Scripps Institute. Members of Scripps’ chemistry department will work alongside Pfizer scientists to adapt these chemical methods for use in creating DELs.
Scripps and Pfizer may choose to expand the scope of the joint research to include other technologies relevant for enabling DEL-based drug discovery. Financial terms of the agreement are not disclosed